

Luxembourg

Tuberculosis profile

Population 2016

<1 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	<0.01 (<0.01–<0.01)	0.18 (0.18–0.19)
Mortality (HIV+TB only)	<0.01 (<0.01–<0.01)	0.13 (0.07–0.22)
Incidence (includes HIV+TB)	0.033 (0.029–0.039)	5.8 (5–6.7)
Incidence (HIV+TB only)	<0.01 (<0.01–<0.01)	0.85 (0.51–1.3)
Incidence (MDR/RR-TB)**	0 (0–0)	0 (0–0)

	Estimated TB incidence by age and sex (thousands)*, 2016		
	0-14 years	> 14 years	Total
Females	<0.01 (<0.01–<0.01)	0.01 (<0.01–0.011)	0.011 (<0.01–0.012)
Males	<0.01 (<0.01–<0.01)	0.021 (0.018–0.025)	0.023 (0.019–0.026)
Total	<0.01 (<0.01–<0.01)	0.031 (0.026–0.036)	0.033 (0.029–0.039)

TB case notifications, 2016	
Total cases notified	29
Total new and relapse	29
- % tested with rapid diagnostics at time of diagnosis	0%
- % with known HIV status	
- % pulmonary	83%
- % bacteriologically confirmed among pulmonary	92%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2016	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.06 (0.04–0.07)

TB/HIV care in new and relapse TB patients, 2016	Number	(%)
Patients with known HIV-status who are HIV-positive		
- on antiretroviral therapy		

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			0 (0–0)
Estimated % of TB cases with MDR/RR-TB	0% (0–0)	0% (0–0)	
% notified tested for rifampicin resistance	93%		27
MDR/RR-TB cases tested for resistance to second-line drugs			1
Laboratory-confirmed cases		MDR/RR-TB: 1, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 1, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New cases registered in 2015		
Previously treated cases registered in 2015		
HIV-positive TB cases registered in 2015		
MDR/RR-TB cases started on second-line treatment in 2014		
XDR-TB cases started on second-line treatment in 2014		

TB preventive treatment, 2016	
% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100–100)

TB financing, 2017	
National TB budget (US\$ millions)	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New cases
— Previously treated cases
— HIV-positive — MDR/RR-TB — XDR-TB